<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>361-MITOTANE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MITOTANE" rxcui="7004">
<ATC code="L01XX23" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the dasabuvir by the mitotane</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>361-MITOTANE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MITOTANE" rxcui="7004">
<ATC code="L01XX23" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SPIRONOLACTONE" rxcui="9997">
<ATC code="C03DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of blockage of the action of the mitotane by the spironolactone</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
